The company says the plant will be fully closed by the end of the first quarter of 2004. A spokesperson for BioReliance tells GlobeSt.com that the company owns the property but it is unclear what its plans are for the site.
BioReliance is in the process of merging with Invitrogen Corp. and Baseball Acquisition Corp., a wholly owned subsidiary of Invitrogen. BioReliance says it made the decision to close this facility to "to optimize capacity utilization among its facilities in the US and the UK and to reduce administrative costs."
The company says it will schedule projects with its Worcester customers either to complete the work prior to closure or to transfer it to BioReliance's other facilities. The costs associated with the planned closure, which are estimated to range from $600,000 to $900,000, will be recorded by the end of the first quarter of 2004.
© Touchpoint Markets, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to asset-and-logo-licensing@alm.com. For more inforrmation visit Asset & Logo Licensing.
